ANALYSIS OF THE RESULTS OF NEODJUVANT TREATMENT IN PATIENTS WITH CONSIDERATION FOR THE IMMUNOPHENOTYPICAL FEATURES OF BREAST CANCER

A. A. Subbotina; Субботина А. А.; V. P. Letyagin; Летягин В. П.; N. N. Tupitsyn; Тупицын Н. Н.; I. V. Vysotskaya; Высоцкая И. В.; V. D. Yermilova; Ермилова В. Д.

doi:10.17650/1994-4098-2008-0-4-31-34

ANALYSIS OF THE RESULTS OF NEODJUVANT TREATMENT IN PATIENTS WITH CONSIDERATION FOR THE IMMUNOPHENOTYPICAL FEATURES OF BREAST CANCER

Authors: Subbotina A.A.¹^,2, Letyagin V.P.¹^,2, Tupitsyn N.N.¹^,2, Vysotskaya I.V.¹^,2, Yermilova V.D.¹^,2
Affiliations:
1. Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
2. Department of Oncology, I.M. Sechenov Moscow Medical Academy
Issue: No 4 (2008)
Pages: 31-34
Section: MAMMOLOGY. NEW TECHNOLOGIES
Published: 17.11.2008
URL: https://ojrs.abvpress.ru/ojrs/article/view/377
DOI: https://doi.org/10.17650/1994-4098-2008-0-4-31-34
ID: 377

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The efficiency of neoadjuvant chemotherapy is directly related to the expression of CD95 (FAS/APO-1) apoptosis receptor on cancer cells, which is confirmed with the pathomorphism and changes of CD95-positive cells during neoadjuvant chemotherapy (the most effective CAF regimen is cyclophosphan, doxorubicin, and 5- fluorouracil).